Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868608 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT00868608 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 81 participants.
The verdict
NCT00868608, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin (CMC-544) in subjects with indolent Non-Hodgkins lymphoma (NHL) that is refractory or has relapsed after multiple therapies including rituximab or radioimmunotherapy. The investigational drug will be given to subjects with indolent NHL by intravenous infusion at a dose of 1.8 mg/m2, every 4 weeks.
Interventions
- DRUG Inotuzumab Ozogamicin (CMC-544)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2009-07-30 |
| Est. Completion | 2013-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00868608
The ClinicalTrials.gov registry entry for NCT00868608 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inotuzumab Ozogamicin (CMC-544) is the first listed.
NCT00868608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00868608 about?
NCT00868608 is a clinical study titled "Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma". The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin (CMC-544) in subjects with indolent Non-Hodgkins lymphoma (NHL) that is refractory or has relapsed after multiple therapies including rituximab or radioimmunotherapy. The investigational drug will be given to subjects wit...
What is the current status of trial NCT00868608?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2009-07-30. Estimated completion is 2013-06-27.
What interventions are being tested in trial NCT00868608?
The interventions under investigation include: Inotuzumab Ozogamicin (CMC-544) (DRUG).
Who is sponsoring clinical trial NCT00868608?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.